FOR HEALTHCARE PROFESSIONALS ONLY

This website is a global information resource. It is intended for healthcare professionals only outside of the United States of America (US) who are interested in information on Foundation Medicine®. This site is not intended to provide medical advice and/or treatment guidance. If you are a US healthcare professional click here.

This site is produced by Roche as a partner of Roche Foundation Medicine.

Please be aware that you are leaving foundationmedicine.ie.
Menu
Close
Our portfolioFoundationOne CDxFoundationOne Liquid CDxFoundationOne Heme

 

 

Our portfolio
 

High-quality portfolio

A portfolio of extensively validated comprehensive profiling services to guide treatment decisions across the patient journey

Foundation Medicine’s portfolio of extensively validated comprehensive genomic profiling services provides powerful insights to guide efficient, personalised treatment decisions – across the patient journey:1–8
EXPLORE EXPLORE
EXPLORE EXPLORE
EXPLORE EXPLORE

All our services use our leading comprehensive genomic profiling approach to identify clinically relevant alterations and potentially expand treatment options

All of Foundation Medicine's services use our leading comprehensive genomic profiling approach, which broadly analyses the tumour genome to identify clinically relevant alterations and potentially expands patients' treatment options.1,2,4,5,7–13
Learn more about comprehensive genomic profilling
Genomic database

 

As our understanding of cancer evolves, so do our tests

Our continuously growing genomic database currently includes over 400,000 genomic profiles in over 150 common and rare tumour subtypes. Advanced bioinformatics interpret the data, including rare and complex alterations, to generate powerful insights.14 Our tests are constantly evolving to capture the most clinically relevant genomic alterations so you stay up-to-date and the latest treatment options can be considered.1,2,4,5

Our growing database includes 200,000+ genomic profiles, allowing our tests to constantly evolve so we can provide the most clinically relevant insights

Date of item: January 2022. M-IE-00000628
References
  1. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
  2. FoundationOne®CDx Technical Specifications. Available at: https://www.foundationmedicine.qarad.eifu.online/foundationmedicine/en/foundationmedicine (Accessed August 2021).
  3. FoundationOne®CDx FDA Approval, 2017. Available at: 
    https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Accessed August 2020).
  4. FoundationOne®Liquid CDx Technical Specifications. Available at: https://www.foundationmedicine.qarad.eifu.online/foundationmedicine/en/foundationmedicine (Accessed August 2021).
  5. Woodhouse, R. et al. Clinical and analytical validation of FoundationOne®Liquid CDx, a novel 324-gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One 2020; 15(9): e0237802. https://doi.org/10.1371/journal.pone.0237802.
  6. FoundationOne®Liquid CDx FDA Approval, 2020. Available at: www.foundationmedicine.com/press-releases/445c1f9e-6cbb-488b-84ad-5f133612b721 (Accessed August 2021).
  7. FoundationOne®Heme Technical Specifications. Available at: https://www.foundationmedicine.qarad.eifu.online/foundationmedicine/en/foundationmedicine (Accessed August 2021).
  8. He J et al. Blood 2016; 127: 3004–3014.
  9. Drilon A et al. Clin Cancer Res 2015; 21: 3631–3639.
  10. Rankin A et al. Oncologist 2016; 21: 1306–1314.
  11. Ross JS et al. Cancer 2016; 122: 2654–2662.
  12. Suh JH et al. Oncologist 2016; 21: 684–691.
  13. Hirshfield KM et al. Oncologist 2016; 21: 1315–1325.
  14. Foundation Insights. Available at: https://www.foundationmedicine.com/insights-and-trials/foundation-insights (Accessed August 2021).